Data Presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Reinforce Baxter International, Inc.'s Commitment to Making GAMMAGARD LIQUID Therapy More Convenient

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) announced data supporting further progress in efforts to make antibody therapy more convenient for patients with primary immunodeficiency (PID), including ways to give patients more options of where, how often and when they receive treatment. The data were presented in three posters at the 2009 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, D.C., on Saturday, March 14.